Becton, Dickinson and Company logo

Becton, Dickinson and Company (BDX) Q2 2026 Earnings

BDX·Reported May 7, 2026·Before market open

Becton, Dickinson and Company reported Q2 2026 revenue of $4.7B (-10.6% YoY), beat analyst consensus of $4.7B by $42.2M. Diluted EPS came in at $2.90 (-13.4% YoY), beat the $2.78 consensus by $0.12. Becton, Dickinson and Company reports across 3 business segments, led by Medical, Life Sciences, and Interventional.

Revenue
$4.7Bbeat by $42.2M
Consensus: $4.7B
Diluted EPS
$2.90beat by $0.12
Consensus: $2.78
SEC

SEC Filings

Earnings release8-K · 0001628280-26-031638
Quarterly report10-Q · 0000010795-26-000026

Financial Snapshot

Trailing eight quarters through Q2 2026

View all metrics

Q2 2026 Earnings FAQ

Common questions about Becton, Dickinson and Company's Q2 2026 earnings report.

Becton, Dickinson and Company (BDX) reported Q2 2026 earnings on May 7, 2026 before market open.

Becton, Dickinson and Company reported revenue of $4.7B and diluted EPS of $2.90 for Q2 2026.

Revenue beat the consensus estimate of $4.7B by $42.2M. EPS beat the consensus estimate of $2.78 by $0.12.

Compared to the same quarter a year prior, revenue declined 10.6% from $5.3B a year earlier and diluted EPS declined 13.4% from $3.35.

You can read the 8-K earnings release (0001628280-26-031638) and the 10-Q periodic report (0000010795-26-000026) directly on SEC EDGAR. The filing index links above go to sec.gov.